DEENOVA
Deenova today announced that it continued its last 2 years market dominance in France with another net new RESAH competitive award for its D3 ACCED mechatronic solutions at Centre Hospitalier Hazebrouck near Dunkerque. Separately, Deenova is pleased to simultaneously announce add-on sales of 4 ASTUS cabinets to existing Deenova customer Centre Hospitalier François Quesnay de Mantes-La-Jolie .
Loïc Bessin , Managing Director of Deenova in France stated: “Combining net new business awards at premier hospital groups like RESAH with Centre Hospitalier Hazebrouck , while at the same time earning the trust of additional add-on sales by previous Deenova customers such as Centre Hospitalier François Quesnay de Mantes-La-Jolie is self-evident proof of Deenova France maturity, showing a high level of continued satisfaction with our automation solutions amongst our existing customer base in France.”
Christophe Jaffuel , Deenova Chief Commercial Officer, added: “I am extremely pleased to continue to witness since 2019 the important and yearly contribution that RESAH ongoing awards means to Deenova in France, renewing its past commitment to Deenova well established mechatronic Unit-Dose solutions like D3 ACCED . I look forward to continuing the market leading cooperation with RESAH in the future.”
Centre Hospitalier Hazebrouck is a public health establishment located in the Lille Métropole healthcare area, and certified by the High Authority for Health in 2019. It assumes the functions of a local hospital for a population of approximately 124,000 inhabitants, with a capacity of 94 hospital beds, centered on medicine, surgery and gynecology-obstetrics, an Emergency Reception Service and a Home Hospitalization service. It also has an accommodation structure for the elderly (EHPAD) with 136 beds, a CSAPA (Centre for Care, Support and Prevention in Addictology) and 20 Aftercare and Rehabilitation beds. Patients benefit from consultations and expert advice as well as a high-quality technical platform with a medical imaging, 4 operating theaters, 3 birthing rooms, a pharmacy and sterilization units with 470 medical and non-medical staff.
Centre Hospitalier François Quesnay de Mantes-La-Jolie is a public health establishment opened in October 1997, bringing together all short-stay services (medicine, surgery, obstetrics), Aftercare and Rehabilitation (SSR), with 612-bed hospital in the Paris metropolitan area, and with a budget of 125 million euros and 175 doctors.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005991/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 09:00:00 CET | Press release
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in
NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 08:44:00 CET | Press release
NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 202629.10.2025 08:00:00 CET | Press release
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023 Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe.
Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 08:00:00 CET | Press release
Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performanc
Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care29.10.2025 07:28:00 CET | Press release
Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/ Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care. Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance. These developments come amid China’s ongoing demographic transformation. By
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom